drugset / Trial / NCT00659425
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
Timeline
- Start
- 2008-09
- Primary completion
- 2014-12
- Completion
- 2014-12
Publications
- Results Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, et al. Pediatric phase 1 trial of moxetumomab pasudotox: activity in chemotherapy refractory acute lymphoblastic leukemia (ALL) . http://cancerres.aacrjournals.org/content/74/19_Supplement/CT230.short
- Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, Sun W, Liang M, Yang J, Kreitman RJ, Lanasa MC, Pastan I. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 5 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 20 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 30 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 32 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 40 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 50 ug/kg | Intravenous |